CAI CARIS LIFE SCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, CARIS LIFE SCIENCES INC reported revenue of $264M (up 45.4% from a year earlier), net income of −$637K and diluted EPS of $0.00; over the last four quarters revenue was $990M and net income $105M; for the fiscal year ended December 2025 revenue was $812M, up 97.0% on the year before.
CAI annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $812M, gross profit n/a, operating income $45.1M, net income −$68.1M (margin -8.4%), EPS −$3.22
- Fiscal year ended Dec 2024: revenue $412M, gross profit n/a, operating income −$257M, net income −$282M (margin -68.4%), EPS −$10.66
- Fiscal year ended Dec 2023: revenue $306M, gross profit n/a, operating income −$320M, net income −$341M (margin -111.5%), EPS −$13.24
CAI quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $264M (up 45.4% year over year), net income −$637K, EPS $0.00
- Quarter ended Mar 31, 2026: revenue $216M (up 78.8% year over year), net income −$510K, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue $293M, net income $82.0M, EPS $8.24
- Quarter ended Sep 30, 2025: revenue $217M (up 113.4% year over year), net income $24.3M, EPS $0.08
- Quarter ended Jun 30, 2025: revenue $181M (up 81.3% year over year), net income −$71.8M, EPS −$7.97
- Quarter ended Mar 31, 2025: revenue $121M, net income −$103M, EPS −$3.57
- Quarter ended Sep 30, 2024: revenue $102M, net income −$67.7M, EPS −$2.59
- Quarter ended Jun 30, 2024: revenue $100M, net income −$66.2M, EPS −$2.54
CAI cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $83.2M, share buybacks $113K
- Fiscal year ended Dec 2024: operating cash flow −$245M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$276M, share buybacks $0
CAI balance sheet
- Jun 30, 2026: cash n/a, total assets $1.23B, total liabilities $638M, shareholders' equity $592M, long-term debt $393M
- Mar 31, 2026: cash $820M, total assets $1.16B, total liabilities $569M, shareholders' equity $593M, long-term debt $381M
- Dec 31, 2025: cash $796M, total assets $1.13B, total liabilities $548M, shareholders' equity $577M, long-term debt $379M
- Sep 30, 2025: cash $753M, total assets $985M, total liabilities $506M, shareholders' equity $478M, long-term debt $376M
- Jun 30, 2025: cash $719M, total assets $955M, total liabilities $502M, shareholders' equity $453M, long-term debt $374M
- Dec 31, 2024: cash $64.0M, total assets $344M, total liabilities $621M, shareholders' equity −$2.50B, long-term debt $319M
What is CAI's revenue?
CARIS LIFE SCIENCES INC reported $990M of revenue over its last four quarters, through June 30, 2026.
Is CAI profitable?
Yes. CARIS LIFE SCIENCES INC earned $105M over the last four quarters.
What is CAI's EPS?
Diluted earnings per share over the last four quarters were $8.32; $0.00 in the latest quarter.